2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.19

PP02.19 - Wenhui Guan

Pdf Summary

The study explores the efficacy and safety of intermittent immune checkpoint inhibitor (ICI) therapy using pembrolizumab in advanced non-small cell lung cancer (NSCLC). The common ICI treatment schedule in NSCLC, typically every three weeks (Q3W), often poses challenges due to adverse events or decisions by physicians. This retrospective study included 27 patients with advanced NSCLC, treated between June 2018 and August 2021. The study cohort predominantly consisted of males (82.1%), with a median age of 60 years. Most participants were in stage IV (70.4%), with a significant portion having lung adenocarcinoma (70.4%).<br /><br />The study aimed to assess the effectiveness of intermittent pembrolizumab therapy, primarily focusing on objective response rate (ORR) and disease control rate (DCR), evaluated through established solid tumor response criteria. The median interval for intermittent therapy was 4.5 weeks, with an average of 33 therapy cycles.<br /><br />The results reported a high ORR of 74.1%, with 14 partial responses and 6 complete responses, and a DCR of 88.9%, including stable disease in four patients. Treatment-emergent adverse events (TEAEs) of any grade were observed in 11.1% of the patients, leading to treatment discontinuation or dose reduction for some.<br /><br />Overall, the study concluded that intermittent ICI therapy presented a valuable balance of manageable safety and promising efficacy for patients with advanced NSCLC, demonstrating the potential for flexible treatment schedules in clinical practice.

Keywords

immune checkpoint inhibitor

pembrolizumab

non-small cell lung cancer

NSCLC

intermittent therapy

objective response rate

disease control rate

treatment-emergent adverse events

retrospective study

lung adenocarcinoma